University of Patras
Έκφραση μεταλλαγμένων τμημάτων του νικοτινικού υποδοχέα της ακετυλοχολίνης και χρήση τους για την ανάπτυξη θεραπείας για τη μυασθένεια
Abstract
dc:descriptionNicotinic acetylcholine receptors (AchRs) are large, transmembrane glycoproteins, which are composed of five homologous subunits and they are divided into two subgroups, the neuronal and the muscle type. The muscle AChRs are located on the postsynaptic membrane of the neuromuscular junction and have the subunit composition α2βγδ or α2βεδ. The muscle AChR is the best studied model as far as its characteristics and function are concerned. Nevertheless, high resolution information about the three-dimensional structure of the human AChR has not been reported so far. In addition to the physiological role of the muscle AChR, which is responsible for mediating the neuromuscular transmission, the muscle AChR is the main pathogenic factor in the autoimmune disease myasthenia gravis (MG). In MG, autoantibodies against the AChR cause loss of the available and functional AChRs in the neuromuscular junction, and as a consequence, the action of acetylcholine is blocked. We have previously expressed the human muscle AChR α1, β1, γ and ε ECDs. These recombinant proteins were purified in a soluble and glycosylated form, recognizable by both monoclonal antibodies and a considerable percentage of anti-subunit antibodies in positive sera from MG patients. However, both the expression yield and the solubility of these proteins were not satisfactory for structural studies. Nevertheless, they were successfully used for a novel, antigen-specific therapeutic approach against MG, regarding the specific removal of the autoantibodies from MG sera, using these proteins as immunoadsorbents. We aimed at the improvement of the structure, solubility and expression yield of the ECDs of the muscle AChR, in order to render them suitable for structural studies and mainly to use them for the amelioration of the antigen-specific therapeutic approach against MG. For this, we selected the γECD, which formed oligomers and displayed a low expression yield and constructed four mutants of the protein. The mutations were concerning the replacement of certain cysteines, which could form inappropriate intra- or inter-molecular bonding and thus aggregation, as well as the substitution of the hydrophobic Cys-loop region by its counterpart, more hydrophilic AChBP Cys-loop. The two mutants which carried the Cys-loop of the AChBP displayed a dramatic improvement at the expression yield and solubility, while they approached the expected molecular size, according to the results from gel filtration and dynamic light scattering. When these two improved mutants were used as immunoadsorbents, they exhibited an increased ability to bind autoantibodies from MG sera, compared with the wild type γECD. These results indicate that the hydrophobic Cys-loop region of the γECD importantly contributes to the formation of aggregates during the expression of the ECD, and consequently followed the replacement of this region at the rest ECDs of the muscle AChR. In order to further ameliorate the antigen-specific therapeutic approach against MG, we carried out efforts to co-express all of the ECDs of the muscle AChR, targeting to create complexes which would carry the interfaces between the ECDs, which are thought to be also immunogenic. At these efforts, the mutant forms of the ECDs which carried the Cys-loop of the AChBP were used. These initial co-expressions of the ECDs were not successful, with the respect to the creation of complexes. In order to combine the ECDs of all the subunits and construct a functional molecule, the next step was the binding of these ECDs with a linker of repeated amino acids. At the beginning were constructed the pairs (concatamers) which were needed in order to follow subclonings, preparative to form the pentamer. All of the concatamers displayed the expected molecular weight. This fact suggests that the linker does not undergo proteolysis, and thus is capable of retaining the subunits conjoint. Furthermore, the expression yield of the concatamers was satisfactory and they retained their ability to bind radiolabelled α-bungarotoxin, which is specifically binds to the α1ECD with high affinity. However, the results from the gel filtration indicated that all the concatamers eluted in a broad spectrum of molecular weights, from monomers to oligomers. With respect to the use of the concatamers at the therapeutic approach against MG, the results showed that all the concatamers retain the ability to bind autoantibodies from MG sera, although there was no further improvement in the immunoadsorbing ability of the single ECDs. Conclusively, the substitution of the hydrophobic Cys-loop of the ECDs by the corresponding, more hydrophilic of the AChBP, results in the construction of molecules with improved characteristics. The molecules are able to be linked together and form concatamers with the appropriate conformation, retaining their functionality. These results demonstrate that it is feasible to construct the heteropentamer of the human muscle AChR, which will consist only of the ECDs.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2009
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Bitzopoulou, Kalliopi
- Μπιτζοπούλου, Καλλιόπη
Subjects
dc:subject × 20- Νικοτινικός υποδοχέας ακετυλοχολίνης
- Μυασθένεια
- Αυτοάνοσο νόσημα
- Νευρομυϊκή σύναψη
- Κύρια ανοσογόνος περιοχή (MIR)
- Αντιγονοειδική θεραπευτική προσέγγιση για τη μυασθένεια
- Ανοσοπροσρόφηση
- Συγκαταμερή
- Nicotinic acetylcholine receptor
- Myasthenia
- Autoimmune diseases
- Neuromuscular junction
- Main immunogenic region (MIR)
- Antigen - specific therapeutic approach for myasthenia
- Immunoadsorption
- Concatamers
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/19186